阅读说明：本技术 黄芪多糖在制备预防和治疗钩端螺旋体病中的医用用途 (Medical application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis ) 是由 曹永国 宋宁 张文龙 谢旭峰 吕天宝 张石磊 丁越 王佳琪 吴殿君 于 2019-12-11 设计创作，主要内容包括：本发明提供了一种黄芪多糖在制备预防和治疗钩端螺旋体病的医用用途。在本发明中,采用黄芪多糖的标准品,以50mg/kg的剂量给对钩端螺旋体敏感的金黄地鼠提前注射黄芪多糖,在感染2X108/ml的钩端螺旋体后,能够有效的控制钩端螺旋体的感染,并且有100%的存活率。本发明拓展了黄芪多糖的药用范围,为黄芪多糖的新用途的开发提供了依据。(The invention provides a medical application of astragalus polysaccharide in preparation of a medicine for preventing and treating leptospirosis. In the invention, the astragalus polysaccharide standard substance is adopted, and the astragalus polysaccharide is injected into golden yellow hamster sensitive to leptospira in advance at the dose of 50mg/kg, so that the infection of the leptospira can be effectively controlled after 2X108/ml of leptospira is infected, and the survival rate is 100 percent. The invention expands the medicinal range of the astragalus polysaccharide and provides a basis for the development of new application of the astragalus polysaccharide.)

1. The astragalus polysaccharide is used for preparing medicines for preventing and treating leptospirosis.

2. The astragalus polysaccharide used as the medicine for preventing and treating leptospira is applicable to any pharmaceutically acceptable carrier.

3. The pharmaceutical preparation is a liquid preparation of astragalus polysaccharide standard substance, β -glucan powder is dissolved and diluted by normal saline according to the dosage, 5mg/ml, and the dosage of β -glucan is 10 mg/kg.

Technical Field

The invention provides a new medical application of astragalus polysaccharide, in particular discloses an application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis, and belongs to the technical field of medicines.

Background

Leptospirosis (Leptospirosis) is a worldwide common zoonotic disease, called Leptospirosis for short, that is associated with occupational or living contacts and with exposure to leptospira, and is highly prevalent in flood-prone areas, and is particularly widespread in developing countries and tropical regions. The disease is susceptible to human and livestock, and the clinical manifestations after infection are various, so that diagnosis is not easy. The pathogen of the leptospirosis can continuously exist in the host, further spread to pollute the environment, infect other people and animals, and cause serious harm. Currently, the methods for preventing and treating leptospira are the injection of vaccines and the use of antibiotics.

The Astragalus polysaccharides are water-soluble heteropolysaccharides obtained by extracting, concentrating and purifying dried root of Astragalus mongholicus (Fisch.) bge or Astragalus membranaceus (Fisch.) bge of Leguminosae, and have light yellow color, fine powder, uniformity, no impurities and hygroscopicity. The Astragalus polysaccharides comprises hexuronic acid, glucose, fructose, rhamnose, arabinose, galacturonic acid and glucuronic acid, can be used as immunopotentiator or regulator, and has antiviral, antitumor, antiaging, radioprotective, anti-stress, and antioxidant effects. However, there are few reports on the prevention and treatment of leptospira.

Disclosure of Invention

The invention aims to provide application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis, including prevention of leptospirosis and treatment after infection. The application of the astragalus polysaccharide can reduce the abuse of antibiotics and can also effectively prevent and control leptospira outbreak.

The invention aims to provide medical application of astragalus polysaccharide in preventing and treating leptospirosis, which comprises the prevention of leptospirosis and the treatment after infection.

The astragalus polysaccharide is used as a medicine for preventing and treating leptospirosis.

The astragalus polysaccharide is used as a medicine for preventing and treating leptospira and is suitable for any pharmaceutically acceptable carrier.

The pharmaceutical preparation is a standard astragalus polysaccharide liquid preparation, and the astragalus polysaccharide powder is dissolved and diluted by normal saline according to the dosage, wherein the dosage is 5mg/ml, and the dosage of the astragalus polysaccharide is 10 mg/kg.

The astragalus polysaccharide can effectively control the infection of leptospira, reduce the inflammatory reaction of each organ and improve the survival rate of golden hamster to 100 percent.

The invention has the positive effects that:

provides a new medical application of astragalus polysaccharide in preparing a medicament for preventing and treating leptospira; carrying out secondary development on the pharmacological action of the compound; the medicinal range of the astragalus polysaccharide is expanded; the invention can effectively reduce the use of antibiotics when treating and preventing leptospirosis, can also effectively prevent and control leptospirosis during outbreak, and has great effect on the healthy development of animal husbandry.

Description of the drawings:

FIG. 1 shows the resistance of golden hamster to Leptospira infection after injection of Astragalus polysaccharides;

FIG. 2 shows the effect of Astragalus polysaccharides on the removal of leptospira in the body;

FIG. 3 shows the protective effect of Astragalus polysaccharides on the major organs of golden hamster;

FIG. 4 shows that Astragalus polysaccharides cause the expression level of important inflammatory factors in the body.

The specific implementation mode is as follows:

the present invention is further illustrated by the following examples, which do not limit the present invention in any way, and any modifications or changes that can be easily made by a person skilled in the art to the present invention will fall within the scope of the claims of the present invention without departing from the technical solution of the present invention.